Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation in mice

Journal of Virology

Volumn 74, Issue 8, 2000, Pages 3832-3841

  Sundaresan, Periasamy ^a,b   Hunter, William D ^a,c   Martuza, Robert L ^a   Rabkin, Samuel D ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b ARAVIND EYE HOSPITAL   (India)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; HERPES SIMPLEX VIRUS 1; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS ATTENUATION; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALS; BRAIN; BRAIN DISEASES; FEMALE; GENE THERAPY; GENETIC VECTORS; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; MICE; MICE, INBRED BALB C; MUTATION; PLAQUE ASSAY; POLYMERASE CHAIN REACTION; VIRUS REPLICATION;

EID: 0034035628     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.8.3832-3841.2000     Document Type: Article

References (88)

1. Andreansky, S. S., B. He, G. Y. Gillespie, L. Soroceanu, J. Markert, J. Chou, B. Roizman, and R. J. Whitley. 1996. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc. Natl. Acad. Sci. USA 93:11313-11318.
2. Baringer, J. R., and P. Pisani. 1994. Herpes simplex virus genomes in human nervous system tissue analyzed by polymerase chain reaction. Ann. Neurol. 36:823-829.
3. Beers, D. R., J. S. Henkel, R. P. Kesner, and W. G. Stroop. 1995. Spatial recognition memory deficits without notable CNS pathology in rats following herpes simplex encephalitis. J. Neurol. Sci. 131:119-127.
4. Bloom, D. C., N. T. Maidment, A. Tan, V. B. Dissette, L. T. Feldman, and J. G. Stevens. 1995. Long-term expression of a reporter gene from latent herpes simplex virus in the rat hippocampus. Mol. Brain Res. 31:48-60.
5. Boviatsis, E. J., J. M. Scharf, M. Chase, K. Harrington, N. W. Kowall, X. O. Breakefield, and E. A. Chiocca. 1994. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther. 1:323-331.
6. Brandt, C. R., P. D. Imesch, N. L. Robinson, N. A. Syed, S. Untawale, S. R. Darjatmoko, R. J. Chappell, P. Heinzelman, and D. M. Albert. 1997. Treatment of spontaneously arising retinoblastoma tumors in transgenic mice with an attenuated herpes simplex virus mutant. Virology 229:2X3-291.
7. Cabrera, C. V., C. Wohlenberg, H. Openshaw, M. Rey-Mendez, A. Puga, and A. L, Notkins. 1980. Herpes simplex virus DNA sequences in the CNS of latently infected mice. Nature 288:288-290.
8. Cameron, J. M., I. McDougall, H. S. Marsden, V. G. Preston, D. M. Ryan, and J. H. Subak-Sharpe. 1988. Ribonucleotide reductase encoded by herpes simplex virus is a determinant of the pathogenicity of the virus in mice and a valid antiviral target. J. Gen. Virol. 69:2607-2612.
9. Chahlavi, A., T. Todo, R. L. Martuza, and S. D. Rabkin. 1999. Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1:162-169.
10. Chou, J., E. R. Kern, R. J. Whitley, and B. Roizman. 1990. Mapping of herpes simplex virus-1 neurovirulence to gamma 34.5, a gene nonessential for growth in culture. Science 250:1262-1266.
11. Chrisp, C. E., J. C. Sunstrum, D. R. J. Averill, M. Levine, and J. C. Glorioso. 1989. Characterization of encephalitis in adult mice induced by intracerebral inoculation of herpes simplex virus type 1 (KOS) and comparison with mutants showing decreased virulence. Lab. Investig. 60:822-830.
12. Coen, D. M., M. Kosz-Vnenchak, J. G. Jacobson, D. A. Leib, C. L. Bogard, P. A. Schaffer, K. L. Tyler, and D. M. Knipe. 1989. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc. Natl. Acad. Sci. USA 86:4736-4740.
13. Corey, L., and P. G. Spear. 1986. Infections with herpes simplex viruses. N. Engl. J. Med. 314:749-757.
14. Desai, P., R. Ramakrishnan, Z. W. Lin, B. Osak, J. C. Glorioso, and M. Levine. 1993. The RR1 gene of herpes simplex virus type 1 is uniquely trans activated by ICPO during infection. J. Virol. 67:6125-6135. (Erratum, 68: 1264, 1994.)
15. Devi-Rao, G. B., D. C. Bloom, J. G. Stevens, and E. K. Wagner. 1994. Herpes simplex virus type 1 DNA replication and gene expression during explant-induced reactivation of latently infected murine sensory ganglia. J. Virol. 68:1271-1282.
16. Dix, R. D., R. R. McKendall, and J. R. Baringer. 1983. Comparative neurovirulence of herpes simplex virus type 1 strains after peripheral or intracerebral inoculation of BALB/c mice. Infect. Immun. 40:103-112.
17. Drummond, C. W., R. P. Eglin, and M. M. Esiri. 1994. Herpes simplex virus encephalitis in a mouse model: PCR evidence for CNS latency following acute infection. J. Neurol. Sci. 127:159-163.
18. Dubin, G., S. Basu, D. L. Mallory, M. Basu, R. Tal-Singer, and H. M. Friedman. 1994. Characterization of domains of herpes simplex virus type 1 glycoprotein E involved in Fc binding activity for immunoglobulin G aggregates. J. Virol. 58:2478-2485.
19. Esiri, M. M. 1982. Herpes simplex encephalitis. An immunohistological study of the distribution of viral antigen with the brain. J. Neurol. Sci. 54:209-226.
20. Fawl, R. L., and B. Roizman. 1993. Induction of reactivation of herpes simplex virus in murine sensory ganglia in vivo by cadmium. J. Virol. 67: 7025-7031.
21. Fink, D. J., L. R. Sternberg, P. C. Weber, M. Mata, W. F. Goins, and J. C. Glorioso. 1992. In vivo expression of β-galactosidase in hippocampal neurons by HSV-mediated gene transfer. Hum. Gene Ther. 3:11-19.
22. Goodman, Z. D., K. G. Ishak, and I. A. Sesterhenn. 1986. Herpes simplex hepatitis in apparently immunocompetent adults. Am. J. Clin. Pathol. 85: 694-699.
23. Gordon, B., O. A. Setnes, J. Hart, Jr., D. F. Hanley, and R. J. Whitley. 1990 Long-term cognitive sequelae of acyclovir-treated herpes simplex encephalitis. Arch. Neurol. 47:646-647.
24. Holland, L. E., K. P. Anderson, J. R. Stringer, and E. K. Wagner. 1979. Isolation and localization of herpes simplex virus type 1 mRNA abundant before viral DNA synthesis. J. Virol. 31:447-462.
25. Hunter, W. D., R. L. Martuza, F. Feigenbaum, T. Todo, T. Mineta, T. Yazaki, M. Toda, J. T. Newsome, R. C. Platenberg, H. J. Manz, and S. D. Rabkin. 1999. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J. Virol. 73:6319-6326.
26. Hunter, W. D., T. Yazaki, S. D. Rabkin, and R. L. Martuza. 1996. Replication-competent viral therapy of tumors in the central nervous system, p. 305-317. In P. R. Lowenstein and L. W. Enquist (ed.), Protocols for gene transfer in neuroscience: towards gene therapy of neurological disorders. John Wiley & Sons, Chichesler, England.
27. Idowu, A. D., E. B. Fraser-Smith, K. L. Poffenberger, and R. C. Herman. 1992. Deletion of the herpes simplex virus type 1 ribonucleotide reductase gene alters virulence and latency in vivo. Antiviral Res. 17:145-156.
28. Jacobson, J. G., D. A. Leib, D. J. Goldstein, C. L. Bogard, P. A. Schaffer, S. K. Weller, and D. M. Coen. 1989. A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. Virology 173: 276-283.
29. Javier, R. T., F. Sedarati, and J. G. Stevens. 1986. Two avirulent herpes simplex viruses generate lethal recombinants in vivo. Science 234:746-748.
30. Jia, W. W., M. McDermott, J. Goldie, M. Cyander, J. Tan, and F. Tufaro. 1994. Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1. J. Natl. Cancer Inst. 86: 1209-1215.
31. Kaplitt, M. G., J. G. Pfaus. S. P. Kleopoulos, B. A. Hanlon, S. D. Rabkin, and D. W. Pfaff. 1991. Expression of a functional foreign gene in adult mammalian brain following in vivo transfer via a herpes simplex virus type 1 defective viral vector. Mol. Cell. Neurosci. 2:320-330.
32. Kaufman, B., S. A. Gandhi, E. Louie, R. Rizzi, and P. Illei. 1997. Herpes simplex virus hepatitis: case report and review. Clin. Infect. Dis. 24:334-338.
33. Kennedy, P. G., J. H. Adams, D. I. Graham, and G. B. Clements. 1988. A clinico-pathological study of herpes simplex encephalitis. Neuropathol. Appl. Neurobiol. 14:395-415.
34. Kesari, S., T. M. Lasner, K. R. Balsara, B. P. Randazzo, V. M. Lee, J. Q. Trojanowski, and N. W. Fraser. 1998. A neuroattenuated ICP34.5-deficient herpes simplex virus type 1 replicates in ependymal cells of the murine central nervous system. J. Gen. Virol. 79:525-536.
35. Kesari, S., V. M. Lee, S. M. Brown, J. Q. Trojanowski, and N. W. Fraser. 1996. Selective vulnerability of mouse CNS neurons to latent infection with a neuroattenuated herpes simplex virus-1. J. Neurosci. 16:5644-5653.
36. Knotts, F. B., M. L. Cook, and J. G. Stevens. 1973. Latent herpes simplex virus in the central nervous system of rabbits and mice. J. Exp. Med. 138: 740-744.
37. Kooby, D. A., J. F. Carew, M. W. Halterman, J. E. Mack, J. R. Bertino, L. H. Blumgart, H. J. Federoff, and Y. Fong. 1999 Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J. 13:1325-1334.
38. Kramm, C. M., N. G. Rainov, M. Sena-Esteves, F. H. Barnett, M. Chase, U. Herrlinger, P. A. Pechan, E. A. Chiocca, and X. O. Breakefield. 1996. Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment. Hum. Gene Ther. 7:1989-1994.
39. Kristensson, K. 1976. Experimental herpes simplex virus infection in the immature mouse brain. Acta Neuropathol. (Berlin) 35:343-351.
40. Kurtz, A., A. Zimmer, F. Schnutgen, G. Bruning, F. Spener, and T. Muller. 1994. The expression pattern of a novel gene encoding brain-fatty acid binding protein correlates with neuronal and glial cell development. Development 120:2637-2649.
41. Lasner, T. M., R. Tal-Singer, S. Kesari, V. M. Lee, J. Q. Trojanowski, and N. W. Fraser. 1998. Toxicity and neuronal infection of a HSV-1 ICP34.5 mutant in nude mice. J. Neurovirol. 4:100-105.
42. Leib, D. A., D. M. Coen, C. L. Bogard, K. A. Hicks, D. R. Yager, D. M. Knipe, K. L. Tyler, and P. A. Schaffer. 1989. Immediate-early regulatory gene mutants define different stages in the establishment and reactivation of herpes simplex virus latency. J. Virol. 63:759-768.
43. Liedtke, W., B. Opalka, C. W. Zimmermann, and E. Lignitz. 1993. Age distribution of latent herpes simplex virus 1 and varicella-zoster virus genome in human nervous tissue. J. Neurol. Sci. 116:6-11.
44. Lopez, C. 1975. Genetics of natural resistance to herpesvirus infection in mice. Nature 258:152-153.
45. Lynas, C., T. J. Hill, N. J. Maitland, and S. Love. 1993. Latent infection with the MS strain of herpes simplex virus type 2 in the mouse following intracerebral inoculation. J. Neurol. Sci. 120:107-114.
46. Lynas, C., K. A. Laycock, S. D. Cook, T. J. Hill, W. A. Blyth, and N. J. Maitland. 1989. Detection of herpes simplex virus type 1 gene expression in latently and productively infected mouse ganglia using the polymerase chain reaction. J. Gen. Virol. 70:2345-2355.
47. MacLean, A. R., M. ul-Fareed, L. Robertson, J. Harland, and S. M. Brown. 1991. Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence. J. Gen. Virol. 72:631-639.
48. 134.5-mutant of herpes simplex virus 1. J. Virol. 71:5560-5569.
49. Martuza, R. L., A. Malick, J. M. Markert, K. L. Ruffner, and D. M. Coen. 1991. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252:854-856.
50. McFarland, D. J., E. Sikora, and J. Hotchin. 1986. The production of focal herpes encephalitis in mice by stereotaxic inoculation of virus. Anatomical and behavioral effects. J. Neurol. Sci. 72:307-318.
51. McGrath, N., N. E. Anderson, M. C. Croxson, and K. F. Powell. 1997. Herpes simplex encephalitis treated with acyclovir: diagnosis and long term outcome. J. Neurol. Neurosurg. Psychiatry. 63:321-326.
52. McKie, E. A., S. M. Brown, A. R. MacLean, and D. I. Graham. 1998. Histopathological responses in the CNS following inoculation with a non-neurovirulent mutant (1716) of herpes simplex virus type 1 (HSV 1): relevance for gene and cancer therapy. Neuropathol. Appl. Neurobiol. 24:367-372.
53. McLean, J. H., M. T. Shipley, D. I. Bernstein, and D. Corbett. 1993. Selective lesions of neural pathways following viral inoculation of the olfactory bulb. Exp. Neurol. 122:209-222.
54. McMenamin, M. M., A. P. Byrnes, H. M. Charlton, R. S. Coffin, D. S. Latchman, and M. J. Wood. 1998. A gamma34.5 mutant of herpes simplex 1 causes severe inflammation in the brain. Neuroscience 83:1225-1237.
55. McMenamin, M. M., A, P. Byrnes, F. G. Pike, H. M. Charlton, R. S. Coffin, D. S. Latchman, and M. J. A. Wood. 1998. Potential and limitations of a γ34.5 mutant of herpes simplex 1 as a gene therapy vector in the CNS. Gene Ther. 5:594-604.
56. Mineta, T., S. D. Rabkin, and R. L. Martuza. 1994. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 54:3963-3966.
57. Mineta, T., S. D. Rabkin, T. Yazaki, W. D. Hunter, and R. L. Martuza. 1995. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1:938-943.
58. Miyatake, S.-I., S. Tani, F. Feigenbaum, P. Sundaresan, H. Toda, O. Narumi, H. Kikuchi, N. Hashimoto, M. Hangai, R. L. Martuza, and S. D. Rabkin. 1999. Hepatoma-specific antitumor activity of an albumin enhancer/ promoter regulated herpes simplex virus in vivo. Gene Ther. 6:564-572.
59. New, K. C. 1996. Ph.D. thesis Georgetown University, Washington, D.C.
60. New, K. C., K. Gale, R. L. Martuza, and S. D. Rabkin. 1998. Novel synthesis and release of GABA in cerebellar granule cell cultures after infection with defective herpes simplex virus vectors expressing glutamic acid decarboxylase. Brain Res. Mol. Brain Res. 61:121-135.
61. Perng, G. C., H. Ghiasi, S. M. Slanina, A. B. Nesburn, and S. L. Wechsler. 1996. High-dose ocular infection with a herpes simplex virus type 1 ICP34.5 deletion mutant produces no corneal disease or neurovirulence yet results in wild-type levels of spontaneous reactivation. J. Virol. 70:2883-2893.
62. Pyles, R. B., and R. L. Thompson. 1994. Evidence that the herpes simplex virus type 1 uracil DNA glycosylase is required for efficient viral replication and latency in the murine nervous system. J. Virol. 68:4963-4972.
63. Pyles, R. B., R. E. Warnick, C. L. Chalk, B. E. Szanti, and L. M. Parysek. 1997. A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum. Gene Ther. 8:533-544.
64. Ramakrishnan, R., D. J. Fink, G. Jiang, P. Desai, J. C. Glorioso, and M. Levine. 1994. Competitive quantitative PCR analysis of herpes simplex virus type 1 DNA and latency-associated transcript RNA in latently infected cells of the rat brain. J. Virol. 68:1864-1873.
65. Randazzo, B. P., S. Kesari, R. M. Gesser, D. Alsop, J. C. Ford, S. M. Brown, A. MacLean, and N. W. Fraser. 1995. Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virology 211:94-101.
66. Robertson, L. M., A. R. MacLean, and S. M. Brown. 1992. Peripheral replication and latency reactivation kinetics of the non-neurovirulent herpes simplex virus type 1 variant 1716. J. Gen. Virol. 73:967-970.
67. Rock, D. L., and N. W. Fraser. 1983. Detection of HSV-1 genome in central nervous system of latently infected mice. Nature 302:523-525.
68. Sanders, V. J., A. E. Waddell, S. L. Felisan, X. M. Li, A. J. Conrad, and W. W. Tourtellotte. 1996. Herpes simplex virus in postmortem multiple sclerosis brain tissue. Arch. Neurol. 53:125-133.
69. Schlitt, M., A. D. Lakeman, E. R. Wilson, A. To, R. W. Acoff, G. R. d. Harsh, and R. J. Whitley. 1986. A rabbit model of focal herpes simplex encephalitis. J. Infect. Dis. 153:732-735.
70. Sedarati, F., R. T. Javier, and J. G. Stevens. 1988. Pathogenesis of a lethal mixed infection in mice with two nonneuroinvasive herpes simplex virus strains. J. Virol. 62:3037-3039.
71. Spivack, J. G., M. U. Fareed, T. Valyi-Nagy, T. C. Nash, J. S. O'Keefe, R. M. Gesser, E. A. McKie, A. R. MacLean, N. W. Fraser, and S. M. Brown. 1995. Replication, establishment of latent infection, expression of the latency-associated transcripts and explant reactivation of herpes simplex virus type 1 gamma 34.5 mutants in a mouse eye model. J. Gen. Virol. 76:321-332.
72. Steiner, I., N. Mador, I. Reibstein, J. G. Spivack, and N. W. Fraser. 1994. Herpes simplex virus type 1 gene expression and reactivation of latent infection in the central nervous system. Neuropathol. Appl. Neurobiol. 20: 253-260.
73. Stevens, J. G. 1993. HSV-1 neuroinvasiveness. Intervirology 35:152-163.
74. Stevens, J. G. 1989. Human herpesviruses: a consideration of the latent state. Microbiol. Rev. 53:318-332.
75. Stroop, W. G., and D. C. Schaefer. 1986. Production of encephalitis restricted to the temporal lobes by experimental reactivation of herpes simplex virus. J. Infect. Dis. 153:721-731.
76. Sze, P., and R. C. Herman. 1992. The herpes simplex virus type 1 ICP6 gene is regulated by a 'leaky' early promoter. Virus Res. 26:141-152.
77. Taha, M. Y., G. B. Clements, and S. M. Brown. 1989. A variant of herpes simplex virus type 2 strain HG52 with a 1.5 kb deletion in RL between 0 to 0.02 and 0.81 to 0.83 map units is non-neurovirulent for mice. J. Gen. Virol. 70:705-716.
78. Thompson, R. L., E. K. Wagner, and J. G. Stevens. 1983. Physical location of a herpes simplex virus type-1 gene function(s) specifically associated with a 10 million-fold increase in HSV neurovirulence. Virology 131:180-192.
79. Toda, M., S. D. Rabkin, and R. L. Martuza. 1998. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum. Gene Ther. 9:2177-2185.
80. Tomlinson, A. H., and M. M. Esiri. 1983. Herpes simplex encephalitis, Immunohistological demonstration of spread of virus via olfactory pathways in mice. J. Neurol. Sci. 60:473-484.
81. Ulbricht, A., I. Farber, and P. Wutzler. 1985 Herpes simplex virus hepatitis in mice: effects of treatment with trisodium phosphonoformate. Acta Virol. 29:493-498.
82. Walker, J. R., K. G. McGeagh, P. Sundaresan, T. J. Jorgensen, S. D. Rabkin, and R. L. Martuza. 1999. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum. Gene Ther. 10:2237-2243.
83. Wang, Q., J. Guo, and W. Jia. 1997. Intracerebral recombinant HSV-1 vector does not reactivate latent HSV-1. Gene Ther. 4:1300-1304.
84. Weil, C. S. 1952. Tables for convenient calculation of median-effective dose (LD50 or ED50) and instructions in their use. Biometrics 8:249-263.
85. Wharton, S. B., N. L. Meyers, and A. A. Nash. 1995. Experimental herpes simplex virus type 1 (HSV-1) infection of the spinal cord and dorsal root ganglia. Neuropathol. Appl. Neurobiol. 21:228-237.
86. Whitley, R. J., E. R. Kern, S. Chatterjee, J. Chou, and B. Roizman. 1993. Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models. J. Clin. Investig. 91:2837-2843.
87. Yamada, Y., H. Kimura, T. Morishima, T. Daikoku, K. Maeno, and Y. Nishiyama. 1991. The pathogenicity of ribonucleotide reductase-null mutants of herpes simplex virus typel in mice. J. Infect. Dis. 164:1091-1097.
88. Yazaki, T., H. J. Manz. S. D. Rabkin. and R. L. Martuza. 1995. Treatment of human malignant meningiomas by G207, a replication-competent multi-mutated herpes simplex virus 1. Cancer Res. 55:4752-756.